As of November 6, 2026, Boundless Bio, Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on June 23, 2026 (Form 8-K, June 23, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Boundless Bio, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Boundless Bio, Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-06-23. Every row below is cited to the filing it comes from, and this page adds each new change as Boundless Bio, Inc. files it.
Layoffs on record: 1 filing or notice, latest 2026-06-23 (layoff filings and notices).
Also on the record for Boundless Bio, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| August 27, 2026 | Stake report, Schedule 13G, by Zachary Hornby | 9.8% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G, by ADAR1 Capital Management, LLC | 8.8% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G/A, by Citadel Securities Group LP | 0.6% of the class | 5%+ stakes | Source |
| June 29, 2026 | Stake report, Schedule 13G, by TANG CAPITAL MANAGEMENT, LLC | 11.3% of the class | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G/A, by Nextech VI GP S.a. r.l. | — | 5%+ stakes | Source |
| February 5, 2026 | Stake report, Schedule 13G/A, by FMR LLC | 12% of the class | 5%+ stakes | Source |
| December 4, 2025 | Stake report, Schedule 13G, by Kenneth Griffin | 6.4% of the class | 5%+ stakes | Source |
| August 14, 2025 | Stake report, Schedule 13G/A, by RA Capital Management, L.P. | — | 5%+ stakes | Source |
Selling to them or working with them? See who runs Boundless Bio, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Boundless Bio, Inc. and the records around it.
Boundless Bio, Inc. elsewhere on the record
- 5%+ stake filings Aug 2026
- Layoff notices Jun 2026
- Who owns it
Companies that share a holder
- ADAR1 Capital Management, LLC also filed stake reports on 29 other companies: InMed Pharmaceuticals, Inc. (Oct 2026), Tenax Therapeutics, Inc. (Sep 2026), Adagio Medical Holdings, Inc. (Aug 2026)
- TANG CAPITAL MANAGEMENT, LLC also filed stake reports on 33 other companies: EyePoint, Inc. (Oct 2026), Skye Bioscience, Inc. (Oct 2026), Nano Dimension Ltd. (Aug 2026)
- Citadel Advisors LLC also filed stake reports on 58 other companies: Quantinuum Inc. (Oct 2026), REALLOYS INC. (Oct 2026), STARFIGHTERS SPACE, INC. (Oct 2026)
Watch Boundless Bio, Inc.
Get an email when Boundless Bio, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Boundless Bio, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Boundless Bio, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Boundless Bio, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
9 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-06-23 | Reported | not named in the filing | 8-K, 2026-06-23 |
New leaders reset buying decisions — get the Full Report on Boundless Bio, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the senior executive at Boundless Bio, Inc., with the record behind each one.
Find candidates like senior executive at Boundless Bio, Inc.Every change, in the filing's words
Reported
Separation Agreements and Consulting Agreements with Mr. Hornby and Drs.
- In connection with the Contemplated Transaction, effective July 1, 2026, Christian Hassig, Ph.D., will cease his role as Boundless Bio's Chief Scientific Officer, and Robert Doebele, M.D., Ph.D., will also cease his role as Boundless Bio's Chief Medical Officer.
- Doebele and Hassig In connection with their departures, each of Mr. Hornby and Drs.
- Doebele and Hassig are expected to enter into a separation agreement with Boundless Bio, effective as of July 1, 2026 (the Separation Agreements).
- In addition, each of Mr. Hornby and Drs.
- Doebele and Hassig entered into a consulting agreement with Boundless Bio, pursuant to which they will provide limited transitional services to Boundless Bio.
- Amended and Restated Offer Letters with Ms. Oien and David Hinkle In connection with the Merger, on June 22, 2026, each of Ms. Oien and David Hinkle entered into an amended and restated offer letter with Boundless Bio, to be effective as of July 1, 2026 (the A&R Offer Letters).
- The transaction bonuses will be payable to Ms. Oien and Mr. Hinkle upon the closing of the Merger, or, if earlier, upon a termination by Boundless Bio without cause, their resignation for good reason or their death or disability.
- Neither Ms. Oien nor Mr. Hinkle will be eligible to earn any annual performance bonus for 2026 or thereafter.
Tools for this story
Each opens in a new tab, filled in for Boundless Bio, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.